Clinical Trials Logo

Clinical Trial Summary

This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. Establish the safety of durvalumab and tremelimumab following radioembolization with selective internal radiation (SIR)-Spheres in patients with microsatellite stable (MSS) metastatic colorectal cancer to the liver.

II. Determine the hepatic response rate of SIR-Spheres followed by durvalumab and tremelimumab in patients with MSS metastatic colorectal cancer to the liver.

SECONDARY OBJECTIVES:

I. Estimate the progression free survival (PFS) and overall survival (OS) of the overall treated population.

II. Describe the overall response rate of the treated population. III. Describe the extra-hepatic response in the treated population (abscopal responses).

TERTIARY OBJECTIVES:

I. Describe intra-tumor immune alterations following SIR-Spheres, and following durvalumab plus tremelimumab in comparison to baseline through serial hepatic metastases biopsies.

II. Describe the immune alterations in the blood following SIR-Spheres and following durvalumab plus tremelimumab.

OUTLINE:

Patients receive durvalumab intravenously (IV) over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03005002
Study type Interventional
Source City of Hope Medical Center
Contact
Status Completed
Phase Phase 1
Start date June 28, 2017
Completion date November 26, 2019

See also
  Status Clinical Trial Phase
Completed NCT01704703 - Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques Phase 2
Recruiting NCT02960282 - Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
Completed NCT01998152 - Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT) N/A
Active, not recruiting NCT03275974 - Glutamine PET Imaging Colorectal Cancer Phase 1
Recruiting NCT03095781 - Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Phase 1
Terminated NCT03111823 - Exercise Program During Chemotherapy in Metastatic Colorectal Cancer N/A
Recruiting NCT04267575 - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites N/A
Recruiting NCT03368963 - TAS102 in Combination With NAL-IRI in Advanced GI Cancers Phase 1/Phase 2
Active, not recruiting NCT01271582 - Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients Phase 4
Active, not recruiting NCT03800602 - Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Phase 2
Completed NCT03112668 - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners N/A
Terminated NCT01550510 - Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA Phase 1/Phase 2
Recruiting NCT02919644 - Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. Phase 2
Recruiting NCT03373188 - VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Phase 1
Active, not recruiting NCT04044430 - Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT01722903 - Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer N/A
Recruiting NCT02809716 - High Definition Single Cell Analysis in Colorectal Cancer
Active, not recruiting NCT03087591 - APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Phase 1
Completed NCT01074385 - Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making N/A
Completed NCT00784446 - First-line Therapy of Stage IV Colorectal Cancer Phase 1/Phase 2